Hologic (HOLX) Set To Divest Medical Aesthetics Business
Zacks Investment Research | Nov 21, 2019 09:44PM ET
In its attempt to focus on core profitable segments, Hologic, Inc. (NASDAQ:HOLX) decided to divest its Cynosure medical aesthetics business. Per the announcement, the company entered a definitive agreement with Clayton, Dubilier & Rice to sell the same.
Per the terms of the agreement, roughly 825 employees will be transferred with the Cynosure business, which is expected to close at the end of calendar year 2019. Hologic expects to receive net cash proceeds of $138 million from the divestment, which is subject to certain closing adjustments.
With the impending divestment, the company expects to witness favorable outcomes as Cynosure has been significantly underperforming since its acquisition in March 2017.
Hologic completed the Cynosure acquisition for $66.00 per share in cash, which corresponds to an equity value of $1.65 billion.
Rationale Behind the Agreement
Hologic’s management believes that divesting the medical aesthetics business will enable it to focus more on other core business segments, including Breast Health, which currently accounts for more than 38% of its total revenues.
Meanwhile, the company aims to keep focusing on smaller tuck-in deals, which have been performing well, thereby strengthening its core franchises.
Share Repurchase Plan
Hologic announced that it entered an accelerated share repurchase (ASR) program to buy back $205 million of its common stock. The ASR will be completed, following a new $205-million share repurchase authorization, which has been approved by management. This is an addition to the company’s ongoing share repurchase authorization, under which $211 million is currently available.
Financial Impact
Hologic began the divestment process of Cynosure before the end of fiscal 2019 but completed the negotiation after releasing its fiscal fourth-quarter results. Per the company, the transaction is expected to result in significant additional non-cash impairment charges, which will be recorded in its GAAP results for the fourth quarter of fiscal 2019.
Hologic expects additional pre-tax impairment charges of $155-$185 million for the fourth quarter of fiscal 2019 to reduce the carrying value of the asset group to its fair value. Following this, the asset group is expected to meet the desired criteria by the first quarter of fiscal 2020.
Get The News You Want
However, these adjustments could lead to further expenses. Additionally, the loss from the divestment is expected to generate a cash tax refund of $300 million in calendar year 2022.
In fiscal 2020, the full impact of the divestment and the ASR are expected to be felt in the form of raised earnings per share on both GAAP and non-GAAP basis.
Price Performance
The company’s shares have risen 16.6% in the past year compared with the Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.